{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:49Z","timestamp":1782337249332,"version":"3.54.5"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.beha.2016.08.011","type":"journal-article","created":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T08:34:39Z","timestamp":1471941279000},"page":"15-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Adoptive cellular therapy for chronic lymphocytic leukemia and B cell malignancies. CARs and more"],"prefix":"10.1016","volume":"29","author":[{"given":"Januario E.","family":"Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.beha.2016.08.011_bib1","first-page":"361","article-title":"Allogeneic bone marrow transplantation for blood cell disorders","volume":"18","author":"Thomas","year":"1982","journal-title":"Birth Defects Orig Artic Ser"},{"issue":"4","key":"10.1016\/j.beha.2016.08.011_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cytogfr.2009.07.004","article-title":"Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited","volume":"20","author":"Decker","year":"2009","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.beha.2016.08.011_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1098\/rspb.1954.0054","article-title":"Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity","author":"Billingham","year":"1954","journal-title":"Proc. R. Soc. London Ser. B"},{"issue":"6","key":"10.1016\/j.beha.2016.08.011_bib4","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood.V35.6.741.741","article-title":"Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia","volume":"35","author":"Buckner","year":"1970","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2016.08.011_bib5","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.beha.2016.08.011_bib6","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/0092-8674(90)90341-B","article-title":"Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation","volume":"60","author":"Goverman","year":"1990","journal-title":"Cell."},{"issue":"20","key":"10.1016\/j.beha.2016.08.011_bib7","doi-asserted-by":"crossref","first-page":"8905","DOI":"10.1073\/pnas.88.20.8905","article-title":"T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins","volume":"88","author":"Letourneur","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.beha.2016.08.011_bib8","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","article-title":"The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways","volume":"64","author":"Irving","year":"1991","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.beha.2016.08.011_bib9","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/mthe.2002.0611","article-title":"A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.beha.2016.08.011_bib10","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2016.08.011_bib11","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J Clin Oncol"},{"issue":"20 Pt 1","key":"10.1016\/j.beha.2016.08.011_bib12","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res."},{"issue":"6","key":"10.1016\/j.beha.2016.08.011_bib13","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2016.08.011_bib14","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.beha.2016.08.011_bib15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.beha.2016.08.011_bib16","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.beha.2016.08.011_bib17","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"224","key":"10.1016\/j.beha.2016.08.011_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"6165","key":"10.1016\/j.beha.2016.08.011_bib19","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.beha.2016.08.011_bib20","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beha.2016.08.011_bib21","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"9967","key":"10.1016\/j.beha.2016.08.011_bib22","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.beha.2016.08.011_bib23","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"132","key":"10.1016\/j.beha.2016.08.011_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.beha.2016.08.011_bib25","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.seminoncol.2015.05.005","article-title":"Adoptive cell therapy\u2013tumor-infiltrating lymphocytes, T-cell receptors, and chimeric antigen receptors","volume":"42","author":"Feldman","year":"2015","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2016.08.011_bib26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/imr.12243","article-title":"Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"263","author":"Gill","year":"2015","journal-title":"Immunol Rev"},{"issue":"6230","key":"10.1016\/j.beha.2016.08.011_bib27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.beha.2016.08.011_bib28","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/0092-8674(91)90327-U","article-title":"Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides","volume":"64","author":"Romeo","year":"1991","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.beha.2016.08.011_bib29","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1158\/1078-0432.CCR-11-1669","article-title":"Stem-like tumor-initiating cells isolated from IL13R\u03b12 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells","volume":"18","author":"Brown","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.beha.2016.08.011_bib30","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2010-04-278218","article-title":"T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies","volume":"117","author":"Shaffer","year":"2011","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.beha.2016.08.011_bib31","doi-asserted-by":"crossref","first-page":"10660","DOI":"10.1073\/pnas.1312789111","article-title":"Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection","volume":"111","author":"Kumaresan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.beha.2016.08.011_bib32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/intimm\/dxw014","article-title":"Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment","volume":"28","author":"Spranger","year":"2016","journal-title":"Int Immunol"},{"issue":"176","key":"10.1016\/j.beha.2016.08.011_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005661","article-title":"Targeting the intracellular WT1 oncogene product with a therapeutic human antibody","volume":"5","author":"Dao","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.beha.2016.08.011_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2999-3_1","article-title":"Peptide antibodies: Past, present, and future","volume":"1348","author":"Houen","year":"2015","journal-title":"Methods Mol Biol."},{"issue":"8","key":"10.1016\/j.beha.2016.08.011_bib35","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.beha.2016.08.011_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2217\/imt.14.108","article-title":"Lentiviral vectors in cancer immunotherapy","volume":"7","author":"Oldham","year":"2015","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.beha.2016.08.011_bib37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/cgt.2014.69","article-title":"Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor","volume":"22","author":"Singh","year":"2015","journal-title":"Cancer Gene Ther"},{"issue":"107","key":"10.1016\/j.beha.2016.08.011_bib38","first-page":"447","article-title":"Contemporary approaches for nonviral gene therapy","volume":"19","author":"Jones","year":"2015","journal-title":"Discov Med"},{"issue":"4","key":"10.1016\/j.beha.2016.08.011_bib39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/CJI.0000000000000032","article-title":"Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity","volume":"37","author":"Rushworth","year":"2014","journal-title":"J Immunother"},{"issue":"2","key":"10.1016\/j.beha.2016.08.011_bib40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/cgt.2014.70","article-title":"Moving from tinkering in the garage to assembly line production: the manufacture of genetically modified T cells expressing chimeric antigen receptors (CARs) comes on line","volume":"22","author":"Cooper","year":"2015","journal-title":"Cancer Gene Ther"},{"issue":"7455","key":"10.1016\/j.beha.2016.08.011_bib41","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1038\/498S17a","article-title":"Perspective: assembly line immunotherapy","volume":"498","author":"Levine","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.beha.2016.08.011_bib42","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1172\/JCI81217","article-title":"Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy","volume":"126","author":"Klebanoff","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beha.2016.08.011_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.5BT1115-524R","article-title":"At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies","volume":"100","author":"Oluwole","year":"2016","journal-title":"J Leukoc Biol"},{"issue":"9","key":"10.1016\/j.beha.2016.08.011_bib44","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4161\/onci.22524","article-title":"How do CARs work?: Early insights from recent clinical studies targeting CD19","volume":"1","author":"Davila","year":"2012","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.beha.2016.08.011_bib45","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.2967\/jnumed.107.047324","article-title":"Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging","volume":"49","author":"Dobrenkov","year":"2008","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.beha.2016.08.011_bib46","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s10875-011-9532-8","article-title":"Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice","volume":"31","author":"Parente-Pereira","year":"2011","journal-title":"J Clin Immunol"},{"issue":"26","key":"10.1016\/j.beha.2016.08.011_bib47","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2016.08.011_bib48","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.beha.2016.08.011_bib49","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.smim.2015.11.003","article-title":"Reprogramming the tumor microenvironment to enhance adoptive cellular therapy","volume":"28","author":"Beavis","year":"2015","journal-title":"Semin Immunol"},{"key":"10.1016\/j.beha.2016.08.011_bib50","doi-asserted-by":"crossref","DOI":"10.1007\/s11307-016-0971-8","article-title":"Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography","author":"Najjar","year":"2016","journal-title":"Mol Imaging Biol"},{"issue":"23","key":"10.1016\/j.beha.2016.08.011_bib51","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1158\/1078-0432.CCR-10-1280","article-title":"Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials","volume":"16","author":"Davis","year":"2010","journal-title":"Clin Cancer Res."},{"issue":"5","key":"10.1016\/j.beha.2016.08.011_bib52","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jcyt.2013.10.013","article-title":"Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy","volume":"16","author":"Barrett","year":"2014","journal-title":"Cytotherapy"},{"key":"10.1016\/j.beha.2016.08.011_bib53","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.9955","article-title":"Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform","author":"Magnani","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.beha.2016.08.011_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.38","article-title":"Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice","volume":"6","author":"Liu","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.beha.2016.08.011_bib55","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-1-62703-260-5_12","article-title":"Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy","volume":"969","author":"Riet","year":"2013","journal-title":"Methods Mol Biol"},{"issue":"11","key":"10.1016\/j.beha.2016.08.011_bib56","article-title":"Long-term follow up of chronic lymphocytic leukemia patients treated with CD40-ligand (CD154) gene therapy","volume":"102","author":"Castro","year":"2003","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2016.08.011_bib57","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1182\/blood.V96.9.2917","article-title":"CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia","volume":"96","author":"Wierda","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.011_bib58","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI1472","article-title":"Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells","volume":"101","author":"Kato","year":"1998","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.beha.2016.08.011_bib59","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/leu.2010.191","article-title":"A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154","volume":"24","author":"Wierda","year":"2010","journal-title":"Leukemia"},{"issue":"15s","key":"10.1016\/j.beha.2016.08.011_bib60","article-title":"Phase I study of intranodal direct injection of adenovirus encoding recombinant CD40-ligand (Ad-ISF35) in patients with chronic lymphocytic leukemia","volume":"27","author":"Castro","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2016.08.011_bib61","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.0712148105","article-title":"Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a","volume":"105","author":"Fukuda","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.beha.2016.08.011_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128151","article-title":"Sleeping beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan receptor-1 (ROR1) into diverse memory T-Cell populations","volume":"10","author":"Deniger","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.beha.2016.08.011_bib63","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"issue":"95","key":"10.1016\/j.beha.2016.08.011_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"174","key":"10.1016\/j.beha.2016.08.011_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004916","article-title":"Transferred WT1-reactive CD8+ T Cells can mediate antileukemic activity and persist in post-transplant patients","volume":"5","author":"Chapuis","year":"2013","journal-title":"Sci Transl Med"},{"issue":"16","key":"10.1016\/j.beha.2016.08.011_bib66","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.beha.2016.08.011_bib67","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2016.08.011_bib68","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol Ther"},{"issue":"20","key":"10.1016\/j.beha.2016.08.011_bib69","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2016.08.011_bib70","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2016.08.011_bib71","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2016.08.011_bib72","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2016.08.011_bib73","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.beha.2016.08.011_bib74","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1182\/blood-2010-10-311845","article-title":"In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor","volume":"117","author":"Giordano Attianese","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2016.08.011_bib75","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","article-title":"Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells","volume":"3","author":"Berger","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.beha.2016.08.011_bib76","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.beha.2016.08.011_bib77","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2046.2046","article-title":"First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL","volume":"126","author":"Qasim","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.08.011_bib78","series-title":"The CAR-T cell-race","author":"Brewer","year":"2015"},{"issue":"11","key":"10.1016\/j.beha.2016.08.011_bib79","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1084\/jem.20030637","article-title":"Exploiting the redundancy in the immune system: vaccines can mediate protection by eliciting \u2018unnatural\u2019 immunity","volume":"197","author":"Casadevall","year":"2003","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.beha.2016.08.011_bib80","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/187153006778250019","article-title":"Targeting tumor-related immunosuppression for cancer immunotherapy","volume":"6","author":"Frumento","year":"2006","journal-title":"Endocr Metab Immune Disord Drug Targets"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T12:31:40Z","timestamp":1601037100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1521692616300135"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.011","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adoptive cellular therapy for chronic lymphocytic leukemia and B cell malignancies. CARs and more","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}